Marta Borges Canha

Dr. Marta Borges Canha

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Open access
MCMarta Borges Canha
Marta Borges Canha
The human colonic mucosa is populated by a wide range of microorganisms, usually in a symbiotic relation with the host. Sometimes this balance is lost and a state of dysbiosis arises, exposing the colon to different metabolic and inflammatory stimuli (according to the microbiota's changing profile). Recent findings lead to hypothesize that this unbalance may create a subclinical pro-inflammatory state that increases DNA mutations and, therefore, colorectal carcinogenesis. In this article we aim to systematically review the scientific evidence regarding colonic microbiota and its role in colorectal carcinogenesis. Systematic review of PubMed searching results for original articles studying microbiota and colorectal cancer until November 2014. Thirty-one original articles studied the role of colon microbiota in colorectal carcinoma including both human and animal studies. Different and heterogeneous methods were used and different bacteria were considered. Nevertheless, some bacteria are consistently augmented (such as Fusobacteria, Alistipes, Porphyromonadaceae, Coriobacteridae, Staphylococcaceae, Akkermansia spp. and Methanobacteriales), while other are constantly diminished in colorectal cancer (such as Bifidobacterium, Lactobacillus, Ruminococcus, Faecalibacterium spp., Roseburia, and Treponema). Moreover, bacteria metabolites amino acids are increased and butyrate is decreased throughout colonic carcinogenesis. Conclusive evidence shows that colorectal carcinogenesis is associated with microbial dysbiosis. This information may be used to create new prophylactic, diagnostic and therapeutic strategies for colorectal cancer.

20 February 2020 in Angiology
Verified
Journal Article
Closed access
PDF file
ALAna Rita Leite
Ana Rita Leite
MCMarta Borges Canha
Marta Borges Canha
RCRita Cardoso
Rita Cardoso
JNJoão Sérgio Neves
João Sérgio Neves
RCRicardo Castro-Ferreira
Ricardo Castro-Ferreira
ALAdelino Leite-Moreira
Adelino Leite-Moreira
Endothelial dysfunction is one of the earliest indicators of cardiovascular (CV) dysfunction, and its evaluation would be of considerable importance to stratify CV risk of many diseases and to assess the efficacy of atheroprotective treatments. Flow-mediated dilation is the most widely used method to study endothelial function. However, it is operator-dependent and can be influenced by physiological variations. Circulating biomarkers are a promising alternative. Due to the complexity of endothelial function, many of the biomarkers studied do not provide consistent information about the endothelium when measured alone. New circulating markers are being explored and some of them are thought to be suitable for the clinical setting. In this review, we focus on novel biomarkers of endothelial dysfunction, particularly endothelial microparticles, endocan, and endoglin, and discuss whether they fulfill the criteria to be applied in clinical practice.

21 September 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
JNJoão Sérgio Neves
João Sérgio Neves
FVFrancisco Vasques‐Nóvoa
Francisco Vasques‐Nóvoa
MCMarta Borges Canha
Marta Borges Canha
ALAna Rita Leite
Ana Rita Leite
ASAbhinav Sharma
Abhinav Sharma
JFJoao Pedro Ferreira
Joao Pedro Ferreira
Aim: To perform a post hoc analysis of the FIGHT trial, evaluating the effect of liraglutide (vs. placebo) on the totality of events in patients with heart failure with reduced ejection fraction (HFrEF). Materials and Methods: FIGHT was a double‐blind randomized controlled trial (RCT) that studied liraglutide versus placebo in 300 recently hospitalized patients with HFrEF followed for 180 days. The main outcome of the present analysis was total events of hospitalizations for heart failure (HF) or all‐cause death. Secondary outcomes included total arrhythmic events and prespecified total events of interest (arrhythmias, sudden cardiac death, acute coronary syndrome, worsening HF, cerebrovascular event, venous thromboembolism, lightheadedness, presyncope/syncope or worsening renal function). Treatment effect was evaluated with negative binomial regression. Results: Compared to placebo, there was a trend towards increased risk with liraglutide of total HF hospitalizations or all‐cause deaths (96 vs. 143 events, incidence rate ratio [IRR] 1.41, 95% confidence interval [CI] 0.98‐2.04; P = 0.064) and total arrhythmias (21 vs. 39, IRR 1.76, 95% CI 0.92‐3.37; P = 0.088). Total prespecified events of interest were increased with liraglutide compared to placebo (196 vs. 295, IRR 1.43, 95% CI 1.06‐1.92; P = 0.018). The risk of HF hospitalizations or all‐cause deaths with liraglutide was higher among patients in New York Heart Association (NYHA) Class III to IV (IRR 1.86, 95% CI 1.21‐2.85) than in those in NYHA Class I to II (IRR 0.62, 95% CI 0.31‐1.23; interaction P = 0.008), and among patients with diabetes (interaction P = 0.051). The risk of arrhythmic events was higher among those without an implanted cardiac device (interaction P = 0.047). Conclusions: In patients with HFrEF, liraglutide might increase the risk of cardiovascular adverse effects, an effect possibly driven by excess risk of arrhythmias and worsening HF events. As this was a post hoc analysis, these results should be interpreted as exploratory and hypothesis‐generating. Further RCTs must be conducted before drawing definitive conclusions.

1 January 2016 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Open access
EDEmanuel Dias-Jácome
Emanuel Dias-Jácome
DLDiogo Libânio
Diogo Libânio
MCMarta Borges Canha
Marta Borges Canha
AGAna Galaghar
Ana Galaghar
PPPedro Pimentel-Nunes
Pedro Pimentel-Nunes
Helicobacter pylori is the strongest risk factor for gastric cancer. However, recent advances in DNA sequencing technology have revealed a complex microbial community in the stomach that could also contribute to the development of gastric cancer. The aim of this study was to present recent scientific evidence regarding the role of non-Helicobacter pylori bacteria in gastric carcinogenesis. A systematic review of original articles published in PubMed in the last ten years related to gastric microbiota and gastric cancer in humans was performed. Thirteen original articles were included. The constitution of gastric microbiota appears to be significantly affected by gastric cancer and premalignant lesions. In fact, differences in gastric microbiota have been documented, depending on Helicobacter pylori status and gastric conditions, such as non-atrophic gastritis, intestinal metaplasia and cancer. Gastric carcinogenesis can be associated with an increase in many bacteria (such as Lactobacillus coleohominis, Klebsiella pneumoniae or Acinetobacter baumannii) as well as decrease in others (such as Porphyromonas spp, Neisseria spp, Prevotella pallens or Streptococcus sinensis). However, there is no conclusive data that confirms if these changes in microbiota are a cause or consequence of the process of carcinogenesis. Even though there is limited evidence in humans, microbiota differences between normal individuals, pre-malignant lesions and gastric cancer could suggest a progressive shift in the constitution of gastric microbiota in carcinogenesis, possibly resulting from a complex cross-talk between gastric microbiota and Helicobacter pylori. However, further studies are needed to elucidate the specific role (if any) of different microorganisms.

7 March 2019 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
CVCatarina Vale
Catarina Vale
JNJoão Sérgio Neves
João Sérgio Neves
MHMadalena von Hafe
Madalena von Hafe
MCMarta Borges Canha
Marta Borges Canha
AMAdelino Leite Moreira
Adelino Leite Moreira

20 February 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
JFJoao Pedro Ferreira
Joao Pedro Ferreira
FSFrancisca Saraiva
Francisca Saraiva
ASAbhinav Sharma
Abhinav Sharma
FVFrancisco Vasques‐Nóvoa
Francisco Vasques‐Nóvoa
AAAntónio Angélico‐Gonçalves
António Angélico‐Gonçalves
JNJoão Sérgio Neves
João Sérgio Neves